Systemic administration of antiangiogenic drugs that target components of the vascular
endothelial growth factor A (VEGF-A; VEGF) signal transduction pathway has become a …

Anti-VEGF–based antiangiogenic drugs are designed to block tumor angiogenesis for
treatment of cancer patients. However, anti-VEGF drugs produce off-tumor target effects on …

Systemic therapy with anti-VEGF drugs such as bevacizumab is widely used for treatment of
human patients with various solid tumors. However, systemic impacts of such drugs in host …

Gynecologic cancer is a major burden in both developed and developing countries. Almost
a half million deaths from gynecologic cancer are reported each year. Understanding the …

Despite setbacks, the clinical development of antiangiogenic agents has accelerated
remarkably over the past 3–4 years. Consequently, there are currently three direct inhibitors …

Induction of angiogenesis represents one of the major hallmarks of cancer. The growth of
new vessels is crucial to provide malignant cells with an adequate supply of oxygen and …

Background The family of vascular endothelial growth factors (VEGF) contains key
regulators of blood and lymph vessel development, including VEGF-A,-B,-C,-D, and …

Multiple angiogenesis inhibitors have been therapeutically validated in preclinical cancer
models, and several in clinical trials. Here we report that angiogenesis inhibitors targeting …

The concept that blood supply is required and necessary for cancer growth and spreading is
intuitive and was firstly formalized by Judah Folkman in 1971, when he demonstrated that …

Abstract Treatment options are insufficient in patients with adrenocortical carcinoma (ACC).
Based on the efficacy of sorafenib, a tyrosine kinase inhibitor, and everolimus, an inhibitor of …